TERT and hepatocellular carcinoma: The OS of HCC patients with TERT mutations was significantly shorter than that of patients without TERT mutations, although there was no significant difference in treatment response and PFS to Atezo/Bev between the two groups, warranting further validation (Matsumae et al., 2022).